Factors associated with non‐use of antipsychotics among older residents with schizophrenia in long‐term institutional care

Alanen, Hanna-Mari; Finne-Soveri, Harriet; Leìnonen, Esa

doi:10.1002/gps.2060

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Racial differences between the incidence of weight gain and clozapine treatment also point to underlying genetic predisposition to antipsychotic induced dyslipidemia (193,194). Drug naïve subjects with schizophrenia have been reported to have a lower incidence of obesity compared to controls (195) and higher incidences of underweight individuals have been reported amongst long term sufferers of the disorder (196). Furthermore, subjects with schizophrenia have also been reported to have lower body mass indices prior to diagnosis (197).…”

Section: Apoe Metabolic Disturbances and Peripheral Drug Effectsmentioning

confidence: 99%

The neurobiology of APOE in schizophrenia and mood disorders

et al. 2011

View full text Add to dashboard Cite

APOE is a major component of several lipoproteins. In addition to its role as a lipid transport protein APOE also serves a dual role as a glial derived, synaptic signalling molecule and thought to play an important role in synaptic plasticity and cognition. Polymorphisms within the APOE gene have been associated with the incidence of Alzheimer's disease. In light of the similarities in the cognitive deficits experienced in both Alzheimer's disease and schizophrenia as well as the comorbidity of depression in Alzheimer's disease, aberrant APOE signalling has been implicated in the pathologies of schizophrenia and mood disorders. The schizophrenia candidate gene, reelin, also shares common receptors with APOE, further supporting a role for APOE in the pathology of these disorders. This review will summarise the current understanding of the involvement of APOE and its receptors in the symptomatology and pathology of schizophrenia and mood disorders and the implications of this involvement for drug treatment.

show abstract

Section: Apoe Metabolic Disturbances and Peripheral Drug Effectsmentioning

confidence: 99%

The neurobiology of APOE in schizophrenia and mood disorders

et al. 2011

View full text Add to dashboard Cite

show abstract

Current awareness in geriatric psychiatry

2009

Int J Geriat Psychiatry

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of geriatric psychiatry. Each bibliography is divided into 9 sections: 1 Reviews; 2 General; 3 Assessment; 4 Epidemiology; 5 Therapy; 6 Care; 7 Dementia; 8 Depression; 9 Psychology. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted

show abstract

Risiken von Antipsychotika im Alter, speziell bei Demenzen 1Prof. Dr. Hans Gutzmann zum 60. Geburtstag gewidmet.

Wolter

2009

Zeitschrift für Gerontopsychologie & -psychiatrie

View full text Add to dashboard Cite

Antipsychotika werden häufig zur Behandlung von herausforderndem Verhalten bei Demenz eingesetzt. Antipsychotika der zweiten Generation («atypische Neuroleptika») spielen dabei mittlerweile eine größere Rolle als die älteren Substanzen. Der nur mäßigen Wirksamkeit stehen schwerwiegende Risiken gegenüber: so ist unter allen Antipsychotika die Mortalität insgesamt erhöht, aber auch das Risiko für plötzlichen Herztod, Schlaganfallereignisse oder venöse Thrombosen. Die Unterschiede zwischen Antipsychotika der ersten und der zweiten Generation sind dabei gering: hochpotente Antipsychotika der ersten Generation führen häufiger zu extrapyramidalmotorischen Symptomen, unter Antipsychotika der zweiten Generation ist das allgemeine Mortalitätsrisiko wahrscheinlich etwas geringer, andererseits wahrscheinlich venöse Thrombosen und metabolische Nebenwirkungen häufiger. Für die übrigen Nebenwirkungen bestehen keine gesicherten Unterschiede. Angesichts der großen Heterogenität der Antipsychotika erscheint der Nutzen einer pauschalen Aufteilung in Antipsychotika der ersten und zweiten Generation fragwürdig. Für die Auswahl einer Substanz sind substanzspezifische Nebenwirkungen, Dosierung, Aufdosierungsgeschwindigkeit sowie Beachtung von Komorbidität, Kontraindikationen und Arzneimittelinteraktionen in Relation zum individuellen Patienten erheblich wichtiger als die Wahl nach bloßer pauschaler Zuordnung zu einer dieser beiden Gruppen. Am wichtigsten ist aber, dass Antipsychotika nur bei klarer Indikation zur Anwendung kommen!

show abstract

Factors associated with non‐use of antipsychotics among older residents with schizophrenia in long‐term institutional care

Abstract: Severe degree of functional impairment and dementia were the main findings associated with non-use of antipsychotics in this resident group.

Cited by 3 publications

References 23 publications

The neurobiology of APOE in schizophrenia and mood disorders

The neurobiology of APOE in schizophrenia and mood disorders

Current awareness in geriatric psychiatry

Risiken von Antipsychotika im Alter, speziell bei Demenzen 1Prof. Dr. Hans Gutzmann zum 60. Geburtstag gewidmet.

Contact Info

Product

Resources

About